文献速递慢阻肺

慢性阻塞性肺疾病的新型治疗:从经验性支气管扩张到精准医学

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine.
PubMed 文献 · Respirology · 2026-03-25

本文综述了2024至2026年间慢阻肺治疗领域的突破性进展,包括三种获FDA批准的新药及靶向2型炎症的生物制剂。文章强调以「可治疗特征」框架指导治疗选择,利用生物标志物实现从症状管理向精准医学的转变。

要点

  • 2024-2026年有三种机制不同的药物获FDA批准,为二十多年来首批实质性药理创新。
  • 生物制剂在嗜酸性粒细胞增多人群中显示减少急性加重的疗效。
  • 「可治疗特征」框架推动慢阻肺管理从诊断分类转向靶向可修饰的病理生物学特征。

核心结论

  • 慢阻肺治疗正从经验性支气管扩张转向基于生物标志物的精准医学。
  • 生物制剂、小分子药物与新兴技术的融合使慢阻肺治疗处于疾病修饰的门槛。

研究设计与样本

  • 这是一篇综合综述,总结了新型慢阻肺治疗药物的新兴证据。
  • 综述评估了生物制剂在嗜酸性粒细胞增多人群中减少急性加重的随机对照试验。

主要发现

  • 三种机制不同的药物获FDA批准,为二十多年来首批实质性药理创新。
  • 生物制剂靶向2型炎症通路(IL-4/IL-13和IL-5轴)在嗜酸性粒细胞增多人群中减少急性加重。
  • 上游警报素拮抗剂(IL-33和胸腺基质淋巴细胞生成素)及基因编辑、衰老细胞清除疗法等新兴技术正在研究中。

关键数值与推荐

  • 生物制剂在嗜酸性粒细胞增多人群中显示减少急性加重。
  • 「可治疗特征」框架用于识别和靶向特定的可修饰病理生物学特征。

临床怎么用

  • 呼吸科医生应利用经过验证的生物标志物选择治疗方案。
  • 在资源有限环境中需考虑药物经济学因素和实施障碍。

局限性

  • 综述指出了需要解决的关键知识空白。
  • 讨论了在资源有限环境中的实施障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator-based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024-2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug Administration approval, marking the first substantive pharmacological innovation in over two decades and catalyzing a fundamental paradigm shift from empirical symptom management towards biomarker-driven, pathobiology-aligned precision medicine. In this comprehensive review, we synthesized emerging evidence on novel COPD therapeutics, encompassing dual phosphodiesterase-3/4 inhibitors, biologics targeting type 2 inflammatory pathways (interleukin [IL]-4/IL-13 and IL-5 axes), upstream alarmin antagonists (IL-33 and thymic stromal lymphopoietin), and emerging technologies including gene editing and senolytic therapy. We evaluated randomized controlled trials reporting reductions in exacerbations with biologic therapy in eosinophil-enriched populations. Central to this transformation is the "treatable traits" framework, in which COPD management shifts from categorical diagnosis towards identification and targeting of specific, modifiable pathobiological characteristics. We provide respiratory physicians with evidence-based guidance for treatment selection by leveraging validated biomarkers, discussing pharmacoeconomic considerations and implementation barriers in resource-limited settings, and identifying critical knowledge gaps requiring resolution. The convergence of biologics, small molecules, and emerging technologies positions COPD therapeutics at the threshold of disease modification.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Fujino, Sugiura. Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine. Respirology. 2026. PMID: 41881492. doi:10.1002/resp.70244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。